Blood Omega-3 and Trans Fatty Acids in Middle-Aged Acute Coronary Syndrome Patients
The authors found much higher levels of omega-3 fatty acids in the blood of patients who did not have acute coronary syndrome compared to patients w/ ACS. Given the sheer volume of research, this really should not surprise anyone. But I will take this time to vent on the felony-like behavior of Reliant Pharmaceuticals. They market Omacor (which recently changed names to Lovaza to protect the guilty..). It is a standard omega-3 fatty acid product.
At best equal to, and most likely inferior to, a number of other omega-3 fatty acid supplements. The difference? Your friendly neighborhood pharmacy charges your insurance anywhere from $115 to $250 for a month’s supply of Omacor. Compare that to around $25 for a similar product. This should be a FELONY. Where is the outrage on this? They certainly don’t need a thousand fold markup for R & D–they didn’t do ANY!!